Viral Population Heterogeneity and Fluctuating Mutational Pattern during a Persistent SARS-CoV-2 Infection in an Immunocompromised Patient.
COVID-19
NGS whole-genome sequencing
SARS-CoV-2
immunocompromised patients
intra-host evolution
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
19 01 2023
19 01 2023
Historique:
received:
21
12
2022
revised:
17
01
2023
accepted:
19
01
2023
entrez:
28
2
2023
pubmed:
1
3
2023
medline:
3
3
2023
Statut:
epublish
Résumé
Literature offers plenty of cases of immunocompromised patients, who develop chronic and severe SARS-CoV-2 infections. The aim of this study is to provide further insight into SARS-CoV-2 evolutionary dynamic taking into exam a subject suffering from follicular lymphoma, who developed a persistent infection for over 7 months. Eight nasopharyngeal swabs were obtained, and were analyses by qRT-PCR for diagnostic purposes. All of them were considered eligible (Ct < 30) for NGS sequencing. Sequence analysis showed that all sequences matched the B.1.617.2 AY.122 lineage, but they differed by few mutations identifying three genetically similar subpopulations, which evolved during the course of infection, demonstrating that prolonged replication is paralleled with intra-host virus evolution. These evidences support the hypothesis that SARS-CoV-2 adaptive capacities are able to shape a heterogeneous viral population in the context of immunocompromised patients. Spill-over of viral variants with enhanced transmissibility or immune escape capacities from these subjects is plausible.
Identifiants
pubmed: 36851504
pii: v15020291
doi: 10.3390/v15020291
pmc: PMC9962589
pii:
doi:
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Front Immunol. 2022 Apr 14;13:860891
pubmed: 35493500
Evol Med Public Health. 2022 Mar 29;10(1):142-155
pubmed: 35419205
Cell. 2021 May 13;184(10):2605-2617.e18
pubmed: 33831372
Infect Drug Resist. 2022 Apr 15;15:1871-1887
pubmed: 35450114
Protein J. 2020 Jun;39(3):198-216
pubmed: 32447571
Clin Infect Dis. 2021 Dec 6;73(11):2144-2145
pubmed: 34009286
Cancer Discov. 2022 Jan;12(1):62-73
pubmed: 34753749
Lancet. 2011 Jan 1;377(9759):42-51
pubmed: 21176949
Virus Evol. 2021 Jul 30;7(2):veab064
pubmed: 34527285
Nat Microbiol. 2021 Jul;6(7):821-823
pubmed: 34108654
Cell Mol Immunol. 2021 Apr;18(4):1067-1069
pubmed: 33664486
Proc Natl Acad Sci U S A. 2020 Oct 6;117(40):24614-24616
pubmed: 32958678
Nat Commun. 2021 Sep 21;12(1):5553
pubmed: 34548480
mSphere. 2021 Aug 25;6(4):e0024421
pubmed: 34319130
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
SN Compr Clin Med. 2021;3(2):670-674
pubmed: 33585797
Infect Genet Evol. 2020 Sep;83:104351
pubmed: 32387564
Nat Commun. 2021 Oct 20;12(1):6103
pubmed: 34671049
mSphere. 2021 Aug 25;6(4):e0048021
pubmed: 34431691
Clin Chem Lab Med. 2007;45(8):1098-104
pubmed: 17868000
Sci Rep. 2022 Jul 21;12(1):12479
pubmed: 35864211
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Cell. 2020 Dec 23;183(7):1901-1912.e9
pubmed: 33248470
Virus Evol. 2022 Aug 26;8(2):veac080
pubmed: 36533153
Science. 2021 Mar 12;371(6534):1139-1142
pubmed: 33536258
Cell. 2021 Apr 29;184(9):2332-2347.e16
pubmed: 33761326
PLoS One. 2022 Mar 25;17(3):e0265453
pubmed: 35333910